Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells

Valentina Russo, Alessia Paciocco, Alessandra Affinito, Giuseppina Roscigno, Danilo Fiore, Francesco Palma, Marco Galasso, Stefano Volinia, Alfonso Fiorelli, Carla Lucia Esposito, Silvia Nuzzo, Giorgio Inghirami, Vittorio de Franciscis, Gerolama Condorelli

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

MicroRNAs (miRNAs) are key regulators of different human processes that represent a new promising class of cancer therapeutics or therapeutic targets. Indeed, in several tumor types, including non-small-cell lung carcinoma (NSCLC), the deregulated expression of specific miRNAs has been implicated in cell malignancy. As expression levels of the oncosuppressor miR-34c-3p are decreased in NSCLC compared to normal lung, we show that reintroduction of miR-34c-3p reduces NSCLC cell survival in vitro. Further, in order to deliver the miR-34c-based therapeutic selectively to tumor cells, we took advantage of a reported nucleic acid aptamer (GL21.T) that binds and inhibits the AXL transmembrane receptor and is rapidly internalized in the target cells. By applying methods successfully used in our laboratory, we conjugated miR-34c to the GL21.T aptamer as targeting moiety for the selective delivery to AXL-expressing NSCLC cells. We demonstrate that miR-34c-3p and the GL21.T/miR-34c chimera affect NSCLC cell proliferation and are able to overcome acquired RTK-inhibitor resistance by targeting AXL receptor. Thus, the GL21.T/miR-34c chimera exerts dual inhibition of AXL at functional and transcriptional levels and represents a novel therapeutic tool for the treatment of NSCLC.

Original languageEnglish
Pages (from-to)334-346
Number of pages13
JournalMolecular Therapy - Nucleic Acids
Volume13
DOIs
Publication statusPublished - Dec 7 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Proliferation
MicroRNAs
Neoplasms
Therapeutics
Nucleic Acids
Cell Survival
Lung

Keywords

  • aptamer
  • lung cancer
  • miRNA
  • NSCLC
  • therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Russo, V., Paciocco, A., Affinito, A., Roscigno, G., Fiore, D., Palma, F., ... Condorelli, G. (2018). Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. Molecular Therapy - Nucleic Acids, 13, 334-346. https://doi.org/10.1016/j.omtn.2018.09.016

Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. / Russo, Valentina; Paciocco, Alessia; Affinito, Alessandra; Roscigno, Giuseppina; Fiore, Danilo; Palma, Francesco; Galasso, Marco; Volinia, Stefano; Fiorelli, Alfonso; Esposito, Carla Lucia; Nuzzo, Silvia; Inghirami, Giorgio; de Franciscis, Vittorio; Condorelli, Gerolama.

In: Molecular Therapy - Nucleic Acids, Vol. 13, 07.12.2018, p. 334-346.

Research output: Contribution to journalArticle

Russo, V, Paciocco, A, Affinito, A, Roscigno, G, Fiore, D, Palma, F, Galasso, M, Volinia, S, Fiorelli, A, Esposito, CL, Nuzzo, S, Inghirami, G, de Franciscis, V & Condorelli, G 2018, 'Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells', Molecular Therapy - Nucleic Acids, vol. 13, pp. 334-346. https://doi.org/10.1016/j.omtn.2018.09.016
Russo, Valentina ; Paciocco, Alessia ; Affinito, Alessandra ; Roscigno, Giuseppina ; Fiore, Danilo ; Palma, Francesco ; Galasso, Marco ; Volinia, Stefano ; Fiorelli, Alfonso ; Esposito, Carla Lucia ; Nuzzo, Silvia ; Inghirami, Giorgio ; de Franciscis, Vittorio ; Condorelli, Gerolama. / Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells. In: Molecular Therapy - Nucleic Acids. 2018 ; Vol. 13. pp. 334-346.
@article{411a7e36b82d465b9786d944cda83510,
title = "Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells",
abstract = "MicroRNAs (miRNAs) are key regulators of different human processes that represent a new promising class of cancer therapeutics or therapeutic targets. Indeed, in several tumor types, including non-small-cell lung carcinoma (NSCLC), the deregulated expression of specific miRNAs has been implicated in cell malignancy. As expression levels of the oncosuppressor miR-34c-3p are decreased in NSCLC compared to normal lung, we show that reintroduction of miR-34c-3p reduces NSCLC cell survival in vitro. Further, in order to deliver the miR-34c-based therapeutic selectively to tumor cells, we took advantage of a reported nucleic acid aptamer (GL21.T) that binds and inhibits the AXL transmembrane receptor and is rapidly internalized in the target cells. By applying methods successfully used in our laboratory, we conjugated miR-34c to the GL21.T aptamer as targeting moiety for the selective delivery to AXL-expressing NSCLC cells. We demonstrate that miR-34c-3p and the GL21.T/miR-34c chimera affect NSCLC cell proliferation and are able to overcome acquired RTK-inhibitor resistance by targeting AXL receptor. Thus, the GL21.T/miR-34c chimera exerts dual inhibition of AXL at functional and transcriptional levels and represents a novel therapeutic tool for the treatment of NSCLC.",
keywords = "aptamer, lung cancer, miRNA, NSCLC, therapeutics",
author = "Valentina Russo and Alessia Paciocco and Alessandra Affinito and Giuseppina Roscigno and Danilo Fiore and Francesco Palma and Marco Galasso and Stefano Volinia and Alfonso Fiorelli and Esposito, {Carla Lucia} and Silvia Nuzzo and Giorgio Inghirami and {de Franciscis}, Vittorio and Gerolama Condorelli",
year = "2018",
month = "12",
day = "7",
doi = "10.1016/j.omtn.2018.09.016",
language = "English",
volume = "13",
pages = "334--346",
journal = "Molecular Therapy - Nucleic Acids",
issn = "2162-2531",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells

AU - Russo, Valentina

AU - Paciocco, Alessia

AU - Affinito, Alessandra

AU - Roscigno, Giuseppina

AU - Fiore, Danilo

AU - Palma, Francesco

AU - Galasso, Marco

AU - Volinia, Stefano

AU - Fiorelli, Alfonso

AU - Esposito, Carla Lucia

AU - Nuzzo, Silvia

AU - Inghirami, Giorgio

AU - de Franciscis, Vittorio

AU - Condorelli, Gerolama

PY - 2018/12/7

Y1 - 2018/12/7

N2 - MicroRNAs (miRNAs) are key regulators of different human processes that represent a new promising class of cancer therapeutics or therapeutic targets. Indeed, in several tumor types, including non-small-cell lung carcinoma (NSCLC), the deregulated expression of specific miRNAs has been implicated in cell malignancy. As expression levels of the oncosuppressor miR-34c-3p are decreased in NSCLC compared to normal lung, we show that reintroduction of miR-34c-3p reduces NSCLC cell survival in vitro. Further, in order to deliver the miR-34c-based therapeutic selectively to tumor cells, we took advantage of a reported nucleic acid aptamer (GL21.T) that binds and inhibits the AXL transmembrane receptor and is rapidly internalized in the target cells. By applying methods successfully used in our laboratory, we conjugated miR-34c to the GL21.T aptamer as targeting moiety for the selective delivery to AXL-expressing NSCLC cells. We demonstrate that miR-34c-3p and the GL21.T/miR-34c chimera affect NSCLC cell proliferation and are able to overcome acquired RTK-inhibitor resistance by targeting AXL receptor. Thus, the GL21.T/miR-34c chimera exerts dual inhibition of AXL at functional and transcriptional levels and represents a novel therapeutic tool for the treatment of NSCLC.

AB - MicroRNAs (miRNAs) are key regulators of different human processes that represent a new promising class of cancer therapeutics or therapeutic targets. Indeed, in several tumor types, including non-small-cell lung carcinoma (NSCLC), the deregulated expression of specific miRNAs has been implicated in cell malignancy. As expression levels of the oncosuppressor miR-34c-3p are decreased in NSCLC compared to normal lung, we show that reintroduction of miR-34c-3p reduces NSCLC cell survival in vitro. Further, in order to deliver the miR-34c-based therapeutic selectively to tumor cells, we took advantage of a reported nucleic acid aptamer (GL21.T) that binds and inhibits the AXL transmembrane receptor and is rapidly internalized in the target cells. By applying methods successfully used in our laboratory, we conjugated miR-34c to the GL21.T aptamer as targeting moiety for the selective delivery to AXL-expressing NSCLC cells. We demonstrate that miR-34c-3p and the GL21.T/miR-34c chimera affect NSCLC cell proliferation and are able to overcome acquired RTK-inhibitor resistance by targeting AXL receptor. Thus, the GL21.T/miR-34c chimera exerts dual inhibition of AXL at functional and transcriptional levels and represents a novel therapeutic tool for the treatment of NSCLC.

KW - aptamer

KW - lung cancer

KW - miRNA

KW - NSCLC

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85054816426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054816426&partnerID=8YFLogxK

U2 - 10.1016/j.omtn.2018.09.016

DO - 10.1016/j.omtn.2018.09.016

M3 - Article

AN - SCOPUS:85054816426

VL - 13

SP - 334

EP - 346

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

SN - 2162-2531

ER -